Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 2340

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 16
Chunk 2340
---
    Supplemental disclosure of cash flow information

    Cash paid for interest
     
    $
    7,555

    $
    1,424,140

    Supplemental disclosures of non-cash investing and financing activities

    Settlement of deferred compensation and severance
     
    $
    1,333,285

    $
    -

    Issuance of common stock upon conversion of preferred stock
     
    $
    2,950,217

    $
    -

    Right-of-use assets acquired through operating leases
     
    $
    -

    $
    801,321

    Purchased equipment not yet paid for
     
    $
    -

    $
    108,715

See accompanying notes to consolidated financial statements.

F-8

OpGen, Inc.

Notes to Consolidated Financial Statements

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. In April 2020, OpGen completed a business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, pursuant to which the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis GmbH”), and certain other assets and liabilities of Curetis N.V., including Ares Genetics GmbH (“Ares Genetics”), a wholly-owned subsidiary of Curetis GmbH (together, “Curetis”).

From inception until November 2023, OpGen operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. In November 2023, Curetis filed a petition for insolvency with the district court of Stuttgart, Germany, and Ares Genetics filed a petition for insolvency with the commercial court in Vienna, Austria. The insolvency proceedings of Curetis and Ares Genetics were adjudicated under the insolvency laws of Germany and Austria, respectively.

The insolvency administrators assumed control over the assets and liabilities of Curetis and Ares Genetics, respectively, which eliminated the authority and power of the Company and its officers